FOR IMMEDIATE RELEASE
May 19, 2025
Published by Population Research Institute
Media release regarding RU486 – the abortion pill as its popularly known, has just been legislated by the NSW Parliament for Midwives and Nurses to administer. A study conducted by the Ethics and Public Policy Centre shows significantly higher risks than authorities including the Australian TGA have admitted. There is currently a petition in the USA for this drug to be reevaluated.
Pro-Life Leaders Urge FDA and HHS to Withdraw Dangerous Abortion Pill
Population Research Institute Joins National Call to Protect Women from Harmful Drug
Front Royal, VA – Population Research Institute is voicing strong support for a newly issued letter from national pro-life leaders urging Health and Human Services Secretary Robert F. Kennedy, Jr. and FDA Commissioner Martin A. Makary to withdraw approval of the abortion pill in light of alarming new safety data.
The letter, sent by pro-life organizations spanning the country, points to a recent analysis of commercial insurance data from over 865,000 patients. It found that more than 94,000 women suffered serious complications within just 45 days of taking the abortion pill—making the drug more than twenty times riskier than the FDA has previously acknowledged. Complications included hemorrhaging, sepsis, infection, and other life-threatening conditions.
Population Research Institute stands in full support of its message and believes that it is urgent that the FDA take immediate action.
“We in the pro-life movement have known for years that the abortion pill kills young moms as well as unborn babies,” said Steven Mosher, President of Population Research Institute. “Anecdotal reports of serious hemorrhaging and infections, as well as deaths, abound.”
The FDA removed key safety reporting requirements in 2016, under the Obama administration, and the Biden administration later made the drug widely available with almost no oversight—despite growing evidence of its risks.
“The FDA was reckless in originally approving this toxic drug,” Mosher continued, “and the Biden administration was even more so when it made it widely available almost without restrictions. It’s past time for HHS and the FDA to withdraw its approval of this dangerous drug.”
Population Research Institute applauds the leaders who signed the letter and joins them in calling on federal agencies to prioritize women’s safety and reevaluate the approval of chemical abortion drugs in light of this disturbing new data.
